Q32 Bio (QTTB) Retained Earnings (2017 - 2026)
Q32 Bio's (QTTB) quarterly Retained Earnings came in at $258.9 million in Q1 2026, up 205.33% year-on-year from $84.8 million in Q1 2025, and up 4.82% quarter-over-quarter from $247.0 million in Q4 2025.
Q32 Bio (QTTB) Retained Earnings (2017 - 2026) Analysis & Trends
Q32 Bio's Retained Earnings history runs 10 years deep, the most recent figure standing at $258.9 million for Q1 2026.
- On a quarterly basis, Retained Earnings rose 205.33% year-over-year to $258.9 million in Q1 2026; TTM through Mar 2026 was $258.9 million, a 205.33% increase from a year earlier, with the FY2025 full-year figure at $247.0 million, up 205.19% from the prior year.
- Retained Earnings rose to $258.9 million in Q1 2026 per QTTB's latest filing, from $247.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $258.9 million in Q1 2026 and bottomed at -$526.0 million in Q3 2023.
- The 5-year median for Retained Earnings is -$220.6 million (2024), against an average of -$172.4 million.
- Across the five-year window, Retained Earnings sank 1202400.0% in 2023 and surged 205.33% in 2026, its largest moves.
- Year by year, Retained Earnings stood at -$404000.0 in 2022, then tumbled by 130092.82% to -$526.0 million in 2023, then surged by 55.36% to -$234.8 million in 2024, then soared by 205.19% to $247.0 million in 2025, then increased by 4.82% to $258.9 million in 2026.
- Per Business Quant, the three latest QTTB Retained Earnings figures stand at $258.9 million (Q1 2026), $247.0 million (Q4 2025), and -$255.3 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Q32 Bio | 215.66 Mn | 164.91 Mn | - | 258.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258.91 Mn |
| Dec 31, 2025 | 247.01 Mn |
| Jun 30, 2025 | -255.33 Mn |
| Mar 31, 2025 | -245.80 Mn |
| Dec 31, 2024 | -234.81 Mn |
| Sep 30, 2024 | -220.60 Mn |
| Jun 30, 2024 | -203.03 Mn |
| Mar 31, 2024 | -186.05 Mn |
| Sep 30, 2023 | -525.98 Mn |
| Jun 30, 2023 | -493.03 Mn |
| Mar 31, 2023 | -182,000.00 |
| Dec 31, 2022 | -404,000.00 |
| Sep 30, 2022 | -394.84 Mn |
| Jun 30, 2022 | -41,000.00 |
| Mar 31, 2022 | -332.03 Mn |
| Dec 31, 2021 | -424.13 Mn |
| Sep 30, 2021 | -390.50 Mn |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | -329.40 Mn |
| Dec 31, 2020 | -328.37 Mn |